DAVOS, Switzerland, March 21, 2014 /PRNewswire/ --
Alimentary Health has today announced the launch of its new pharmabiotic subsidiary, Alimentary Health Pharma Davos (AHPD) at World Immune Regulation Meeting (WIRM) in Davos, Switzerland.
AHPD scientists at WIRM VIII will present mechanistic data from new studies which consider a novel approach to the management of systemic inflammation. Building on the science of a patented and well documented probiotic culture Bifidobacterium infantis 35624 (B. infantis 35624), the research provides a possible roadmap to identify anti-inflammatory effects beyond the gut in patients with inflammatory conditions such as psoriasis. Greater understanding of this mechanism may provide new pathways for drug development and other therapeutic options.
Commenting on the launch of AHPD, Alimentary Health co-founder and CEO, Dr. Barry Kiely said:
"Alimentary Health has over a decade of experience working on anti-inflammatory bacteria from the human microbiome. The launch of AHPD represents a logical extension of our expertise in this area. This is ground-breaking work, which, could result in an entirely new platform for the management of inflammatory diseases and the potential for exciting new drugs and therapies."
Dr Liam O'Mahony, CSO at AHPD, commented:
"This is exciting science and we are delighted to be able to conduct this important work here in Switzerland, collaborating with the Swiss Institute of Allergy and Asthma Research (SIAF), to pave the way for a deeper understanding of the link between GI health and inflammatory conditions."
Alimentary Health, founded in 1999, is a spin-out company from University College Cork (UCC) and a founding member of the Alimentary Pharmabiotic Centre (APC). The APC at UCC has received global recognition as one of the world's leading institutions in probiotic research and has already seen significant commercial success globally as a result of strategic alliances with leading global healthcare players. Alimentary Health licensed the probiotic strain B. infantis 35624 to Procter & Gamble (P&G) in 2005 who today market B. infantis 35624 under the brand name Align® in the US and Canada. Align® is the number one Gastroenterologist-recommended probiotic product in the US.
More information on the Swiss Institute of Allergy and Asthma Research (SIAF) can be found at http://www.siaf.uzh.ch
SOURCE Alimentary Health